MedTrace Logo

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

NCT00715039 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 169

Last updated 2008-10-03

No results posted yet for this study

Summary

The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.

Conditions

  • Anxiety Disorders

Interventions

DRUG

lorazepam

1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days

DRUG

placebo

placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine

DRUG

paroxetine

20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Completion
2004-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00715039 on ClinicalTrials.gov